

PEER-REVIEW REPORT

Name of journal: *World Journal of Diabetes*

Manuscript NO: 85159

Title: MicroRNA-155 mediates endogenous Angiotensin II Type 1 receptor regulation: implications for innovative Type 2 Diabetes Mellitus management

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05111420

Position: Peer Reviewer

Academic degree: PhD

Professional title: Attending Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: Thailand

Manuscript submission date: 2023-04-14

Reviewer chosen by: Geng-Long Liu

Reviewer accepted review: 2023-05-04 03:17

Reviewer performed review: 2023-05-04 06:58

Review time: 3 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation

Scientific significance of the conclusion in this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Thanks for the invitation for reviewing the paper. Major concerns: 1.As we see, author commented miRNA-155 based on Lopez review, however ,the correlation between the two is not very closed.For instance,“MiR-155 is of particular interest in the Lopez review as it is intricately involved in the pathogenesis of DM as well as in the regulation of AT1R and Ang II effects[6, 8-12].”No “MiR-155” was mentioned in Lopez review. This article can be reassembled into article type of review . 2.If the article type is letter,the author should focus how could “MiR-155” act as a modulator on ACEI or ARBs?.And make the article more shorter. After thorough read, I can only get the correlation with Lopez review. here:“Lopez et al justifiably propose effective interventions through AT1R substrate modulation (ACEi) and/or receptor inhibition (ARBs) to improve glucose homeostasis[6]. Strategies to increase an ailing MIR-155 production in T2DM could prove to be a more appropriate course of action.” 2.The author mentioned miR-155“Minimally detected under normal physiological conditions and mainly expressed in the thymus and spleen ” and “In T2DM, miR-155 levels in plasma, peripheral blood cells, platelets, and urine are significantly and consistently decreased,



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

with surprising congruence between different ethnicities".So how to detect miR-155? Minor concerns: 1."The syndemic of coronavirus disease 2019 (COVID-19) and T2DM has affirmed the latter's lethal effect". Why COVID-19 with T2DM became a latter's lethal effect.The affects of Renin-Angiotensin System on COVID-19 can be detailed.You can delete this sentence or move this part to discussion on relationship between miR-155 and diabetes. 2."We suggest additional pathways that can modulate AT1R and Ang II effects that are of importance for the pathogenesis of IR, T2DM, and the development of cardiovascular and renal diabetic complications."This sentence can move behind"Since a particular miRNA may target one or many different mRNAs while one mRNA may bind many miRNAs, the host can modulate response feedback, through regulatory gene networks, in a concerted effort to control diverse aspects of cellular processes[7]. "like "additional pathways such as :miRNA can modulate..." Final comment This paper reviews "miR-155" from a new perspective that relationship between miR-155 and DM.As a "letter" type ,the content of paper could be more focused and based on Lopez review. As a "review" type, the conclusion of the paper is not convinced. This paper need major revision.

PEER-REVIEW REPORT

Name of journal: *World Journal of Diabetes*

Manuscript NO: 85159

Title: MicroRNA-155 mediates endogenous Angiotensin II Type 1 receptor regulation: implications for innovative Type 2 Diabetes Mellitus management

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05430684

Position: Peer Reviewer

Academic degree: MD, MSc, PhD

Professional title: Consultant Physician-Scientist, Research Fellow

Reviewer's Country/Territory: Greece

Author's Country/Territory: Thailand

Manuscript submission date: 2023-04-14

Reviewer chosen by: Geng-Long Liu

Reviewer accepted review: 2023-05-03 07:24

Reviewer performed review: 2023-05-09 09:01

Review time: 6 Days and 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation

Scientific significance of the conclusion in this manuscript	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input checked="" type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

I have carefully studied the manuscript entitled "MiRNA-155 mediates endogenous Angiotensin II Type 1 receptorregulation: implications for innovative Type 2 Diabetes Mellitus management" by Papadopoulos et al. The topic of MicroRNAs in diabetes mellitus is of growing interest and much evidence has been accumulated the last few years. The authors comment on miR-155 effects in type 2 DM, stating that miR-155 is consistently reduced in serum and tissues in T2DM, and propose that strategies to increase an ailing miR-155 production in T2DM might be beneficial. The manuscript, though interesting, exceeds 1,500 words and contains 50 references. Therefore, before considering publication, the authors are kindly proposed to consider resubmitting the manuscript in the form of Minireview.

PEER-REVIEW REPORT

Name of journal: *World Journal of Diabetes*

Manuscript NO: 85159

Title: MicroRNA-155 mediates endogenous Angiotensin II Type 1 receptor regulation: implications for innovative Type 2 Diabetes Mellitus management

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06140863

Position: Peer Reviewer

Academic degree: PhD

Professional title: Academic Research, Assistant Professor, Research Scientist

Reviewer's Country/Territory: Spain

Author's Country/Territory: Thailand

Manuscript submission date: 2023-04-14

Reviewer chosen by: Geng-Long Liu

Reviewer accepted review: 2023-05-25 07:34

Reviewer performed review: 2023-06-03 09:27

Review time: 9 Days and 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation

Scientific significance of the conclusion in this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The authors have developed an interesting manuscript in the context of the involvement of miRNAs in type 2 diabetes; specifically miR-155. It is a well-developed and coherent letter to the editor. In addition, it contains a significant amount of information contrasted with the appropriate use of bibliographic citations. The work is good, but to improve the quality of the manuscript, I would like to add three suggestions: 1. short title: it contains many abbreviations, perhaps it is not adequate. 2. Full name of the miRNA: in the databases it appears as hsa-miR-155-3p or 5p in humans (or mmu in mice). Is there homogeneity in the nomenclature used in the academic articles consulted? 3. What kind of studies are evidenced by the results described in the table? It would be important to clarify whether they are in vitro, in vivo, or cohort studies, and the experimental techniques used.

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: *World Journal of Diabetes*

Manuscript NO: 85159

Title: MicroRNA-155 mediates endogenous Angiotensin II Type 1 receptor regulation: implications for innovative Type 2 Diabetes Mellitus management

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05430684

Position: Peer Reviewer

Academic degree: MD, MSc, PhD

Professional title: Consultant Physician-Scientist, Research Fellow

Reviewer's Country/Territory: Greece

Author's Country/Territory: Thailand

Manuscript submission date: 2023-04-14

Reviewer chosen by: Li Li

Reviewer accepted review: 2023-06-19 06:54

Reviewer performed review: 2023-06-19 07:13

Review time: 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Peer-reviewer	Peer-Review: <input type="checkbox"/> Anonymous <input checked="" type="checkbox"/> Onymous



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
<https://www.wjgnet.com>

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The authors have successfully revised the manuscript according to the reviewers' suggestions. The quality of the manuscript has been ameliorated. The present form deserves publication as is.